Monitor initial sales data and customer reviews post-launch on August 25. The key question is whether Dermata can generate any meaningful revenue from this direct-to-consumer skincare product. Given the $4M market cap, even small revenue numbers could move the stock, but the lack of pre-orders or guidance makes this a high-risk wait-and-see event.
Price Chart
Executive Summary
Dermata Therapeutics announced via an 8-K that its first commercial product, Tome Foundational Treatment, will launch on August 25, 2026, priced at $178 per set (four once-weekly treatments). This marks the company's shift from a clinical-stage biotech to a commercial skincare company, but with a $4M market cap and no revenue history, the financial impact of this consumer product launch is highly uncertain and unlikely to be material in the near term.
Key Facts
- Dermata expects Tome Foundational Treatment to be available for sale starting August 25, 2026.
- The product will be sold exclusively at www.tomeskincare.com for $178 per set (approximately $45/treatment).
- The set includes four once-weekly treatments.
- This is Dermata's first commercial product, marking a shift from a clinical-stage biotech to commercializing skincare products.
- The company has a market cap of approximately $4M.
Financial Impact
Product priced at $178 per set. No revenue projections or unit sales guidance provided. At a $4M market cap, even modest sales could be significant relative to current valuation, but the consumer skincare market is highly competitive and the company has no commercial track record.
Risk Factors
- No revenue history or commercial infrastructure for consumer products.
- Extremely low market cap ($4M) makes the stock highly volatile and susceptible to any negative news or lackluster sales.
- The skincare market is crowded and dominated by established brands with large marketing budgets.
- The company is shifting from a pharmaceutical R&D model to a consumer goods model, which requires a completely different skill set and capital allocation strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036109 |
| Document: 0001493152-26-036109-index-headers.html | 0001493152-26-036109 |
| Document: 0001493152-26-036109-index.html | 0001493152-26-036109 |
| Document: 0001493152-26-036109.txt | 0001493152-26-036109 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 7d ago | EFFECT | $0.8000 $0.8640 | ▼ −8.00% | ▼ −9.18% | $0.7550 (+5.63%) |
Oct 9, 2026 18d ago | S-3 | $0.8896 $0.8599 | ▼ −3.34% | ▼ −3.33% | $0.7550 (−15.13%) |
Aug 17, 2026 10w ago | 8-K | $1.46 $1.43 | ▲ +2.05% | ▲ +1.38% | $0.7550 (+48.29%) |
Aug 5, 2026 11w ago | 8-K | $1.17 $1.11 | ▼ −5.13% | ▼ −4.97% | $0.7550 (−35.47%) |
Feb 25, 2026 34w ago | 8-K | $1.25 $1.20 | ▼ −4.00% | ▼ −3.52% | $0.7550 (−39.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers